Malte Roerden
@RoerdenM
Followers
174
Following
569
Statuses
84
Physician-scientist interested in cancer immunology and immunotherapy | Postdoc in the Spranger lab @kochinstitute @MIT
Cambridge, MA
Joined October 2019
RT @viditbhandarkar: Excited to share our review that’s now out in @SciImmunology. We describe how DC-T cell interactions in lymph nodes sp…
0
3
0
RT @jitcancer: Meet the Author: Malte Roerden (@RoerdenM), a physician-scientist from @kochinstitute, is 1st author of “Neoantigen architec…
0
3
0
RT @OncoDailyIO: How different immune evasion mechanisms interfere with immunoediting of evolving tumors - @RoerdenM
@stefanispranger @Nat…
0
2
0
RT @jitcancer: Check out the recent #JITC Editor Pick from Malte Roerden et al, "Neoantigen architectures define immunogenicity and drive i…
0
2
0
Very excited to share our recent work now published in @NatRevImmunol! We reviewed how immune evasion mechanisms interfere with immunoediting to fosters intratumor heterogeneity (ITH) and discuss data on the role of ITH itself in blunting anti-tumor immunity. @stefanispranger
Cancer immune evasion, immunoediting and intratumour heterogeneity
0
1
4
Thank you @jitcancer for the nice summary of our latest project where we studied how different neoantigen expression patterns impact anti-tumor immunity 👇
Here’s a closer look at #JITC article: “Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression” by authors @RoerdenM @stefanispranger from @kochinstitute 1/11
0
0
0
RT @LabWaggoner: Low doses of MHC-II-restricted neoantigen peptides induce cytotoxic Tr1 CD4 T cells that kill cDC1 and suppress cancer imm…
0
23
0
RT @Ludwig_Cancer: Ludwig @MIT's @StefaniSpranger chaired a session at #AACR2024 on the crosstalk between various myeloid cells & T cells i…
0
11
0
RT @LabWaggoner: Combining tumor-targeting antibodies with IL-2 mRNA induces rejection of MHC class I-deficient tumors otherwise resistant…
0
4
0
RT @KlebanoffLab: 🚨👇🏻A fantastically creative approach for solving the challenge of safely enhancing T cell potency for adoptive immunother…
0
26
0
RT @JessicaCStark: We are hiring at multiple levels to join our team @MITdeptofBE @kochinstitute Apply below! Postd…
0
91
0
RT @JCI_insight: Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2:
0
6
0
RT @kochinstitute: “We may be close to a new revolution of cancer vaccines.” If you missed our Cancer Vaccines symposium this summer, we’v…
0
8
0